Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450049 | 0.83 | NR1H2 (0.60) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6461216 | 0.83 | NPC1 (0.60) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6452524 | 0.83 | DCUN1D1 (0.50) | CYP1A2CYP3A4CYP2C19NPC1ALPL | |
| SCHEMBL6453486 | 0.83 | ADORA2A (0.60) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL13377809 | 0.81 | CCR1 (0.54) | KDM4ENPC1ALPLRAB9ASMN1; SMN2 | |
| SCHEMBL6454147 | 0.81 | MEN1 (0.41) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6448592 | 0.81 | SMN1; SMN2 (0.67) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL12270088 | 0.78 | CCR1 (0.58) | KDM4EHSD17B10METAP2CCR1CCR8 | |
| SCHEMBL17279723 | 0.77 | NR1H2 (0.64) | KDM4ECYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6451138 | 0.75 | KDM4E (0.47) | KDM4ECYP3A4NPC1ALPLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | KDM4E 3106/4885CYP1A2 47/4885CYP3A4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.